Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab Addition to B-cell Depletion in RRMS
NCT04767698Phase 2Terminated
- Sponsor
- Johns Hopkins University
- Start
- Oct 2021
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of belimumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Johns Hopkins University. Started Oct 2021; status: terminated.
02
Drugs
belimumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT04767698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04767698.